Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Emerald Bioscience Joins Biosecurity Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News

Emerald Bioscience Joins Biosecurity Alliance

Government-industry consortium dedicated to development of vaccines, therapeutics and diagnostics against biological threats in the U.S.

By: Contract Pharma

Contract Pharma Staff

Emerald Bioscience, Inc. has joined the Alliance for Biosecurity, based in Washington, DC, which is composed of biosecurity industry leaders dedicated to the research and development of vaccines, therapeutics and diagnostics against biological threats, including bioterrorism pathogens and emerging infectious diseases.

“It is an honor for EMBI to join this consortium that advocates for public policies and funding to support an array of public health responses to chemical, biological, radiological and nuclear threats, including the rapid development, production, stockpiling, and distribution of critically needed medical countermeasures,” said Brian Murphy, MD, Emerald Bioscience CEO, who also has extensive experience in both basic science research and clinical drug development against infectious diseases.

“We are pleased to welcome EMBI as the 21st member of the Alliance for Biosecurity,” said Alliance for Biosecurity Chair Chris Frech. “It is important that we have well-rounded industry knowledge to address global public health threats. Including EMBI’s innovative approach in our collective voice allows the Alliance to accurately represent industry in these situations.”

“EMBI has been involved in addressing infections related to resistant organisms since our anti-infective program was inaugurated in late 2015 to develop a cannabinoid cocktail against methicillin resistant Staphylococcus aureus (MRSA). We plan to expand that established program to assess activity against other types of bacterial, as well as viral, threats to society,” said Dr. Murphy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics